anti-VEGF
New anti-VEGF therapies seeking Aussie approval
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens ...
Liberal and Labor vow to maintain intravitreal injection MBS rebate
Macular Disease Foundation Australia (MDFA) has had an undertaking by both major political parties that they won’t implement an MBS ...
Beovu obtains DME indication in Europe
The European Commission (EC) has approved anti-VEGF therapy Beovu (brolucizumab) 6 mg for diabetic macular edema (DME), marking the therapy’s ...
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
Ophthalmology’s most life-changing procedures revealed
Seventy-five percent of ophthalmic interventions investigated in a major study have shown evidence of improving quality of life for patients ...
Anti-VEGF becomes most expensive drug on PBS
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a ...
Eylea biosimilar embarks on Phase 3 trial
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial ...
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from ...
Traces of anti-VEGF drugs found in breast milk
Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use ...